File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A Group-Comparative, Randomized, Double-Blind Comparison of the Efficacy and Efficiency of Two Fixed Daily Dose Regimens (100- and 200-IU) of Recombinant Follicle Stimulating Hormone (rFSH, Puregon®) in Asian Women Undergoing Ovarian Stimulation for IVF/ICSI

TitleA Group-Comparative, Randomized, Double-Blind Comparison of the Efficacy and Efficiency of Two Fixed Daily Dose Regimens (100- and 200-IU) of Recombinant Follicle Stimulating Hormone (rFSH, Puregon®) in Asian Women Undergoing Ovarian Stimulation for IVF/ICSI
Authors
Issue Date2002
PublisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=1058-0468
Citation
Journal of Assisted Reproduction and Genetics, 2002, v. 19 n. 10, p. 470-476 How to Cite?
AbstractPurpose : To compare the efficacy, efficacy and safety of a fixed daily dose of recombinant FSH (Puregon®) of a 100- and 200-IU regimen in Asian women undergoing ovarian stimulation for IVF/ICSI. Methods : This was a prospective, randomized, double-blind, multicenter (n = 9) study. Prior to the start of rFSH, all women were pretreated with a gonadotropin releasing hormone agonist (GnRH-a) for pituitary downregulation. Results : A total of 330 women were treated with rFSH: 163 subjects with 100 IU and 167 subjects with . In the 200 IU treatment group, significantly more oocytes were retrieved compared to the 100 IU group (9.6 vs. 5.0 oocytes, p < 0.001). The total dose rFSH needed to develop at least three follicles with a diameter of ≥17 mm was significantly lower in the 100 IU treatment group (1194 vs. 2034 IU, p < 0.001). Although more cycle cancellations were seen in the 100 IU group (24 vs. 13%), the ongoing pregnancy rate per started cycle was comparable between both groups (16.6% in the 100 IU group vs. 15.0% in the 200 IU group). Conclusions : The use of a 100 IU fixed dose is less effective in terms of the number of oocytes retrieved and the higher cancellation rate, but more efficient as indicated by a lower total recombinant FSH dose needed.
Persistent Identifierhttp://hdl.handle.net/10722/222190
ISSN
2015 Impact Factor: 1.858
2015 SCImago Journal Rankings: 0.858
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorNg, EHY-
dc.contributor.authorHoomans, EHM-
dc.contributor.authorMulder, BB-
dc.date.accessioned2015-12-30T06:48:52Z-
dc.date.available2015-12-30T06:48:52Z-
dc.date.issued2002-
dc.identifier.citationJournal of Assisted Reproduction and Genetics, 2002, v. 19 n. 10, p. 470-476-
dc.identifier.issn1058-0468-
dc.identifier.urihttp://hdl.handle.net/10722/222190-
dc.description.abstractPurpose : To compare the efficacy, efficacy and safety of a fixed daily dose of recombinant FSH (Puregon®) of a 100- and 200-IU regimen in Asian women undergoing ovarian stimulation for IVF/ICSI. Methods : This was a prospective, randomized, double-blind, multicenter (n = 9) study. Prior to the start of rFSH, all women were pretreated with a gonadotropin releasing hormone agonist (GnRH-a) for pituitary downregulation. Results : A total of 330 women were treated with rFSH: 163 subjects with 100 IU and 167 subjects with . In the 200 IU treatment group, significantly more oocytes were retrieved compared to the 100 IU group (9.6 vs. 5.0 oocytes, p < 0.001). The total dose rFSH needed to develop at least three follicles with a diameter of ≥17 mm was significantly lower in the 100 IU treatment group (1194 vs. 2034 IU, p < 0.001). Although more cycle cancellations were seen in the 100 IU group (24 vs. 13%), the ongoing pregnancy rate per started cycle was comparable between both groups (16.6% in the 100 IU group vs. 15.0% in the 200 IU group). Conclusions : The use of a 100 IU fixed dose is less effective in terms of the number of oocytes retrieved and the higher cancellation rate, but more efficient as indicated by a lower total recombinant FSH dose needed.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=1058-0468-
dc.relation.ispartofJournal of Assisted Reproduction and Genetics-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/10.1023/A:1020358419073-
dc.subject.meshFertility Agents, Female - therapeutic use-
dc.subject.meshFertilization in Vitro - methods-
dc.subject.meshFollicle Stimulating Hormone - administration & dosage - adverse effects - therapeutic use-
dc.subject.meshOvulation - drug effects - physiology-
dc.subject.meshRecombinant Proteins - administration & dosage - adverse effects - therapeutic use-
dc.titleA Group-Comparative, Randomized, Double-Blind Comparison of the Efficacy and Efficiency of Two Fixed Daily Dose Regimens (100- and 200-IU) of Recombinant Follicle Stimulating Hormone (rFSH, Puregon®) in Asian Women Undergoing Ovarian Stimulation for IVF/ICSI-
dc.typeArticle-
dc.identifier.emailNg, EHY: nghye@hkucc.hku.hk-
dc.identifier.authorityNg, EHY=rp00426-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1023/A:1020358419073-
dc.identifier.pmid12416651-
dc.identifier.pmcidPMC3455678-
dc.identifier.hkuros78440-
dc.identifier.volume19-
dc.identifier.issue10-
dc.identifier.spage470-
dc.identifier.epage476-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats